INHIBITION BY ETOMOXIR OF CARNITINE PALMITOYLTRANSFERASE-I REDUCES HEPATIC GLUCOSE-PRODUCTION AND PLASMA-LIPIDS IN NONINSULIN-DEPENDENT DIABETES-MELLITUS

被引:85
作者
RATHEISER, K
SCHNEEWEISS, B
WALDHAUSL, W
FASCHING, P
KORN, A
NOWOTNY, P
ROHAC, M
WOLF, HPO
机构
[1] UNIV VIENNA, MED KLIN 1, DIV CLIN ENDOCRINOL & DIABETOL, LAZARETTGASSE 14, A-1090 VIENNA, AUSTRIA
[2] BYK GULDEN LOMBERG GMBH, CONSTANCE, GERMANY
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1991年 / 40卷 / 11期
关键词
D O I
10.1016/0026-0495(91)90214-H
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To detemine the therapeutic effect of the carinitine palmitoyltransferase I (CPT-I) inhibitor, etomoxir, eight hospitalized obese non-insulin-dependent diabetes mellitus (NIDDM) patients were studied (body mass index [BMI], 28.7 ± 1.3 kg/m2; age, 54 ± 8 years [means ± SE]) at baseline (placebo = t1), and after oral etomoxir (50 mg/d = t2, 100 mg = 3, 150 mg = t4, 200 mg = t5, placebo = t6). Fasting blood glucose (mmol/L), triglycerides (mmol/L), cholesterol (mmol/L), free fatty acids (μmol/L), β-hydroxybutyrate (μmol/L), and alanine aminotransferase (GPT, U/L) were determined (t1 to t6), as were glucose utilization (M value; indirect calorimetry) and hepatic glucose production during a 10 mU/kg · min euglycemic clamp (t1 and t4). A dose-dependent decrease was induced by etomoxir in fasting blood glucose (t1 to t5: 9.5 ± 0.7, 8.7 ± 1.0, 8.3 ± 1.1, [P v t1 < .05], 7.8 ± 0.9, [P v t1 < .01], 7.9 ± 1.1 [P v t1 < .05]), which was reversible in t6 (9.9 ± 1.1). Mean plasma lipids were reduced (t1 v t5) for triglycerides (-54%, P v t1 < .01), cholesterol (-24%, P v t1 < .05), and β-hydroxybutyrate (-44%, P v t2 < .01), while free fatty acids increased by 52% (P v t1 < .05), as did GPT (t1: 17 ± 3; t5: 32 ± 7 U/L [P v t 1 < .01]). In parallel, hepatic glucose production (mg/min · m2) decreased ( t1 t4: 88 ± 7 73 ± 8 [P v t1 < .05]), whereas M values, ( 263 ± 27 268 ± 29 mg/min · m2), carbohydrate oxidation ( 90 ± 8 74 ± 9 mg/min · m2), and fat oxidation ( 21 ± 7 28 ± 6 mg/min · m2) remained unchanged during the 10-mU/kg · min euglycemic clamp. It is concluded that etomoxir reduces hepatic glucose production, fasting blood glucose, and lipidemia-triglycerides, cholesterol, and β-hydroxybutyrate included-without affecting glucose utilization (M value) during a hyperinsulinemic euglycemic clamp. Such a pharmacologic profile might be helpful in treating hyperlipidemic NIDDM. © 1991.
引用
收藏
页码:1185 / 1190
页数:6
相关论文
共 35 条
[1]   OPERATION OF RANDLES CYCLE IN PATIENTS WITH NIDDM [J].
BEVILACQUA, S ;
BUZZIGOLI, G ;
BONADONNA, R ;
BRANDI, LS ;
OLEGGINI, M ;
BONI, C ;
GELONI, M ;
FERRANNINI, E .
DIABETES, 1990, 39 (03) :383-389
[2]  
BLIESATH H, 1986, DIABETOLOGIA, V29, pA519
[3]   A SYSTEMATIC METHOD FOR VALIDATION OF GAS-EXCHANGE MEASUREMENTS [J].
DAMASK, MC ;
WEISSMAN, C ;
ASKANAZI, J ;
HYMAN, AI ;
ROSENBAUM, SH ;
KINNEY, JM .
ANESTHESIOLOGY, 1982, 57 (03) :213-218
[4]  
DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
[5]  
EISTETTER K, 1986, Drugs of the Future, V11, P1034
[6]   CARBOHYDRATE AND LIPID OXIDATION IN NORMAL AND DIABETIC SUBJECTS [J].
FELBER, JP ;
MAGNENAT, G ;
CASTHELAZ, M ;
GESER, CA ;
MULLERHESS, R ;
KALBERMATTEN, ND ;
EBINER, JR ;
CURCHOD, B ;
JEQUIER, E .
DIABETES, 1977, 26 (07) :693-699
[7]   GLUCOSE STORAGE AND OXIDATION IN DIFFERENT DEGREES OF HUMAN OBESITY MEASURED BY CONTINUOUS INDIRECT CALORIMETRY [J].
FELBER, JP ;
MEYER, HU ;
CURCHOD, B ;
ISELIN, HU ;
ROUSSELLE, J ;
MAEDER, E ;
PAHUD, P ;
JEQUIER, E .
DIABETOLOGIA, 1981, 20 (01) :39-44
[8]  
FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133
[9]   STUDY ON LIPID-METABOLISM IN OBESITY DIABETES [J].
GOLAY, A ;
FELBER, JP ;
MEYER, HU ;
CURCHOD, B ;
MAEDER, E ;
JEQUIER, E .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (02) :111-116
[10]  
GYKGULDEN, 1984, 14784 INT RES REP